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Abstract
Despite the fact that epithelial ovarian cancers are the leading cause of death from gynecological cancer, very little is known
about the pathophysiology of the disease. Mutations in the WNT and PI3K pathways are frequently observed in the human
ovarian endometrioid adenocarcinomas (OEAs). However, the role of WNT/b-catenin and PTEN/AKT signaling in the etiology
and/or progression of this disease is currently unclear. In this report we show that mice with a gain-of-function mutation in
b-catenin that leads to dysregulated nuclear accumulation of b-catenin expression in the ovarian surface epithelium (OSE)
cells develop indolent, undifferentiated tumors with both mesenchymal and epithelial characteristics. Combining
dysregulated b-catenin with homozygous deletion of PTEN in the OSE resulted in development of significantly more
aggressive tumors, which was correlated with inhibition of p53 expression and cellular senescence. Induced expression of
both mTOR kinase, a master regulator of proliferation, and phosphorylation of its downstream target, S6Kinase was also
observed in both the indolent and aggressive mouse tumors, as well as in human OEA with nuclear b-catenin accumulation.
Ectopic allotransplants of the mouse ovarian tumor cells with a gain-of-function mutation in b-catenin and PTEN deletion
developed into tumors with OEA histology, the growth of which were significantly inhibited by oral rapamycin treatment.
These studies demonstrate that rapamycin might be an effective therapeutic for human ovarian endometrioid patients with
dysregulated Wnt/b-catenin and Pten/PI3K signaling.
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Introduction
Ovarian cancer is the most deadly gynecological cancer among
women in the United States with approximately 22,000 new cases
diagnosed and 15,000 deaths yearly, the vast majority of which are
from metastatic epithelial-derived ovarian tumors. The prognosis
is poor because most patients are diagnosed during the late stage of
the disease, when ovarian cancer has already metastasized and the
survival rate is less than 30% [1,2]. The cell of origin and course of
disease progression is not well defined because cancer is usually
diagnosed at an advanced stage [3]. The prevailing theory is that
these tumors originate in the ovarian surface epithelium (OSE), a
single layer of mesothelial cells covering the surface of the ovary
[4], by a mechanism that might involve the formation of cortical
inclusion cysts during rupture and repair after ovulation or from
ovarian atrophy with aging [3].
Ovarian epithelial tumors are classified into five different major
histological categories: serous, endometrioid, mucinous, clear cell,
and undifferentiated [5]. It is not known whether a specific
combination of genetic mutations force the OSE cells to acquire
the specific lineage or whether tumors arise first and acquire more
mutations leading to or commensurate with their commitment to
Mu ¨llerian metaplasia later during the course of disease develop-
ment. The latter hypothesis is well supported by studies in various
mouse models of ovarian cancer in which initial OSE derived
cancerous growths are undifferentiated [2,6,7].
Wnt signaling is essential for normal ovarian development and
various members of the canonical Wnt signaling pathway are
expressed in the ovary [8,9]. Mutations in the b-catenin, APC,
Axin1, and Axin2 genes are associated with ovarian epithelial
cancers [10,11]. Dysregulated WNT/b-catenin signaling plays an
important role in the development of human ovarian endome-
trioid adenocarcinomas (OEAs) but is rare in other types of
ovarian cancer. For example, mutations in exon 3 of b-catenin,
which lead to its stabilization and nuclear accumulation [12], are
present in an estimated 16%–38% of human OEAs [11,13]. In the
present report, we have investigated the mechanisms of tumori-
genesis in murine OSE cells with deletion of exon 3 of b-catenin
and/or Pten. We show that the mTOR pathway is activated in
mice with dysregulated WNT/b-catenin and Pten/PI3K signal-
ing, as well as in human OEAs. We also show evidence that
rapamycin decreases tumor burden in allotransplants of the tumor
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20715cells, suggesting that human OEAs might be a good target for
rapamycin therapy.
Materials and Methods
Mouse genetics and husbandry
All protocols involving animal experimentation were approved
by the MGH Institutional Animal Care and Use Committee
(Protocol# 2005N000195). The mice used in this study were
maintained on C57BL/6;129/SvEv mixed genetic background and
housed under pathogen free standard animal housing conditions as
described [14]. The following parental mice alleles—Ctnnb1
tm1Mmt
[12], Pten
tm1Hwu [15], Amhr2
tm3(cre)Bhr [16]—were used in the crosses
and are hereafter called Ctnnb1
fl(ex3) or Ctnnb1
D(ex3), Pten
fl,o rPten
D/D,
and Amhr2-Cre, respectively. The genotyping of mice was performed
with standard PCR protocols using DNA collected from tail
biopsies. The PCR conditions for Ctnnb1
fl(ex3) and Amhr2
tm3(cre)Bhr are
previously described [12,17,18]. The Pten
fl allele was detected with
primers 59-ACTCAAGGCAGGGATGAGC-39 and 59-
GCCCCGATGCAATAAATATG-39, for 35 cycles of 94 C for
30 sec, 60 C for 1 min, and 72 C for 1 min using Taq DNA
polymerase (Roche).Thegrossimageswere takenwithaNikonD60
digital camera with a macro lens.
Histology and Immunofluorescence
The methods used for histology, IF, and IHC have been
previously described [19]. IF and/or IHC was performed on
tissues derived from minimum of three different animals per
genotype. The whole tissue sections and/or at least three
independent random areas of section at 106 were examined for
specific markers staining and representative images are presented.
The tissue blocks for human ovarian endometrioid adenocarcino-
mas (n=4) and normal/benign ovarian samples (n=3) were
obtained from the Department of Pathology, MGH using
Institutional Review Board-approved protocols. To examine
epithelial glands, whole mouse ovarian tumors (n=6) were cut
into multiple pieces. The tumors blocks were serially sectioned and
every 4
th section was stained for pancytokeratin or cytokeratin 8.
The primary and secondary antibodies used in this study are
described in Table 1. AlexaFluor secondary antibodies (1:500,
Invitrogen, Carlsbad, CA), biotinylated donkey anti-mouse or
anti-rabbit antibody Fab2 (1:1000, Jackson ImmunoResearch
Laboratories, West Grove, PA), and DAB kit (Vector laboratories,
Burlingame, CA) were used in this study. For senescence analysis,
normal and mutant ovaries were collected and fixed overnight in
4% paraformaldehyde. The following day, frozen sections were
cut and SAb-gal staining was performed as instructed by the
manufacturer (Cell Signaling Technology, Danvers, MA). Images
were taken with a Nikon T2000 microscope equipped with an
epifluorescence attachment and a Spot digital camera (Diagnostic
Instruments, Sterling Heights, MI).
Primary tumor cell isolation, transplantation to NOD/
SCID mice, and rapamycin treatments
Primary ovarian tumors were derived from the Amhr2-
Cre;Ctnnb1
D(ex3)/+;Pten
D/D mice. Cells from the primary tumors
were isolated, diluted (2610
6 cells/mouse) in 1:1 Matrigel (BD
Biosciences), and injected subcutaneously into female NOD/SCID
mice (The Jackson Laboratory, Bar Harbor, ME). Grafted mice
were divided into two groups (n=5/group) and administered
200 ml rapamycin (250 mg/dose, Rapamune, Wyeth, PA) or
vehicle control (kindly donated by The American Lecithin
Company, Oxford, CT) twice/week by oral gavage. After 10
weeks of treatment, tumors were excised for analysis. All animals
were euthanized after 12 weeks.
Western blot analyses
Western analyses of ovarian cells collected from a minimum of 3
age-matched control and mutant mice were performed as
previously described [20]. b-actin was used as a loading control.
The experiments were repeated three times. Granulosa cells were
isolated from mice 24 h after they were injected with pregnant
mare’s serum gonadotropin by puncturing the follicles with a
tuberculin syringe.
Tumor Morphometrics
At the end of study, tumor volume was calculated based on
caliper measurements of the exposed tumor using the formula for
an ellipsoid: 4/3 p61/2 length6(1/2 width)
2 [21]. Terminal
deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling
(TUNEL) staining was performed per the manufacturer’s
instructions (Roche, Indianapolis, IN). For estimation of the total
number of pH3-, active caspase 3- and TUNEL-positive cells,
images from three different tumors derived from three different
animals were taken at equivalent gain settings using a microscope
(Nikon TE 2000-S; Micro Video Instruments, Avon, MA)
equipped with a Spot digital camera. pH3-, active caspase 3-,
and TUNEL-positive cells, and DAPI stained nuclei were counted
with the nucleus-counting plugin of Image J software (v1.37, NIH,
Table 1. Antibodies used in this study for IHC, IF and Western blot (WB) analyses.
ANTIGEN SUPPLIER
p19
ARF , p21 Abcam, Cambridge, MA
Activated Caspase 3, b-catenin BD Transduction Laboratories, San Jose, CA
Vimentin, AMH, p16
INK4A Santa Cruz Biotechnology, Santa Cruz, CA
Inhibin-a Biogenes, San Ramon, CA
pH3, c-H2AX Millipore, Bellerica, MA
a-SMA-Cy3, b-catenin Sigma Chemical Co., St. Louis, MO
AKT, phosphoAKT, Pten, p53, mTOR, pmTOR, S6K, pS6K, and p27kip1 Cell Signaling Technologies, Danvers, MA
Pan-cytokeratin Neomarkers, Fremont, CA
Cytokeratin 8 Developmental studies hybridoma bank, IA
b-actin Neomarkers, Fremont, CA
doi:10.1371/journal.pone.0020715.t001
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Adobe systems Inc., San Jose, CA).
Statistical analysis
The unpaired t test was used to test for differences between
groups and p,0.05 was considered statistically significant.
Statistical analyses were performed using Prism software (Graph-
Pad Software, San Diego, CA).
Results
Deregulated Wnt/b-catenin signaling in human and
mouse ovarian tumors
Because mutations in Wnt/b-catenin signaling components are
frequently observed in human OEAs patients [11,13], we
examined b-catenin protein expression in human OEA tissue
samples and observed nuclear accumulation of b-catenin, which is
Figure 1. Overactive Wnt/b-catenin in human OEAs and mutant Amhr2-Cre;Ctnnb1
D(ex3)/+ mice. (A) Membranous b-catenin expression in
normalpostmenopausalhumanovariansurfaceepithelium(OSE)wasdetectedbyimmunofluorescence.(B–D)Nuclearb-catenininrepresentativetissue
samples obtained from three different human OEA patients. b-catenin protein expression in control Ctnnb1
D(ex3)/+ (E) and in Amhr2-Cre;Ctnnb1
D(ex3)/+ (F)
ovaries of 4-week-old mice. Insert in Panels E and F are higher magnification images of follicles to show membranous b-catenin expression in granulosa
cells. (G) Higher magnification image of area indicated with a white arrowhead in panel F. (H) Western blot analyses of b-catenin in protein lysate
obtained from granulosa cells, remnant (remaining ovarian tissue after granulosa cell isolation including ovarian surface epithelium), whole control
(Ctnnb1
D(ex3)/+) andmutant(Amhr2-Cre;Ctnnb1
D(ex3)/+) 4-week-oldovaries, tumors from themutant(Amhr2-Cre;Ctnnb1
D(ex3)/+) 6-month-old ovaries. White
arrows in A, E, F, and G mark the ovarian surface epithelial cells. Nuclei are stained with DAPI. Bars=50 um.
doi:10.1371/journal.pone.0020715.g001
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Only membranous b-catenin protein expression was observed in
OSE of normal human ovary (Fig. 1A). To confirm that activated
Wnt/b-catenin signaling can initiate the formation of OEAs, we
developed a b-catenin gain-of-function mouse model by condition-
ally deleting exon 3 (Ex3) of the b-catenin gene (Ctnnb1), which
contains the phosphorylation sites of b-catenin required for its
ubiquitination and subsequent degradation [12]. Deletion of exon 3
leads to formation of a degradation-resistant but functional form of
b-catenin, which accumulates in the cytoplasm and nuclei of cells
[12]. Amhr2-cre mice were used to mate with mice with a flox allele
of b-catenin, Ctnnb1
fl(ex3)/+ because Amhr2 is expressed in OSE and
Amhr2 promoter-driven Cre causes efficient recombination in OSE
cells [2,19,22,23,24]. In order to verify whether activation of b-
catenin occurs in OSE cells of Amhr2-Cre;Ctnnb1
D(ex3)/+ ovaries, we
analyzed expression of b-catenin. Examination of four-week-old
mice showed nuclear accumulation of b-catenin in OSE and OSE-
derived lesions present throughout the cortex of the mutant Amhr2-
Cre;Ctnnb1
D(ex3)/+ ovaries (Fig. 1F & G)). In contrast, only
membranous b-catenin expression was observed in the OSE of
age matched control ovaries (Fig. 1E). Membranous b-catenin
expression was also observed in the granulosa cells of both mutant
and control Ctnnb1
fl(ex3)/+ ovaries (Fig. 1E & F, inserts). We next
performed western blot analyses on ovarian lysates and demon-
strated the presence of full length and exon 3-deleted b-catenin in
the granulosa cell-depleted residual ovarian cells, including those
from OSE and tumor in the mutant animals (Fig. 1H). A relatively
weaker band of exon 3-deleted b-catenin was detected in the
granulosa cells of the mutant ovaries indicating that very low
recombination occurred in granulosa cells, which is consistent with
the largely membranous staining observed in Fig. 1F or that the
granulosacell preparationswerecontaminatedwith ovarian stromal
cells.
Histological examination of adult mutant ovaries ($12-wks of
age) revealed the presence of pre-tumoral nests of cells in all the
ovaries examined in this study (n=10) (Fig. S1C–E). The
cancerous cells were also present between the ovarian bursa and
OSE (Fig. S1C–E). Nuclear b-catenin was observed in these pre-
tumoral nests, indicating that these lesions were derived from
Amhr2-cre expressing cells (Fig. S1F). Ovaries from age-matched
control mice appeared morphologically normal (Fig. S1A & B).
Even though pretumoral lesions were present in the ovaries of all
young Amhr2-Cre;Ctnnb1
D(ex3)/+ mice, advanced tumor develop-
ment only occurred in approximately 50% of mice by the age of 8-
month to 1-year (Fig. 2). While the majority of the tumors were
undifferentiated (Fig. 2A & B), epithelial glands, which are
characteristic of ovarian endometrioid adenocarcinomas, were
observed in 5/6 mice examined (Fig. 2C). Immunostaining with
cytokeratin 8 (CK8), an epithelial cell specific marker, confirmed
the presence of epithelial glands in these tumors (Fig. 2D). CK8-
specific staining was also observed in early pretumoral lesions, as
well as in undifferentiated tumors, indicative of the epithelial cell
origin of these tumors (Fig. 2F). In control ovaries, CK8 staining
was only observed in the ovarian surface epithelium and oviductal
epithelial cells (Fig. 2E). Because the less differentiated areas of
Amhr2-Cre;Ctnnb1
D(ex3)/+ tumors showed weak staining for CK8
and had a more spindle shape morphology, we examined the
Figure 2. Histological examination of ovarian tumors formed in
Amhr2-Cre;Ctnnb1
D(ex3)/+ mice ovaries. H&E staining of mutant
ovaries (Panels A–C). Panels B & C are magnified views of boxed areas
in Panel A. Cytokeratin 8 (CK8) immunofluorescence on a serial section
(D) of panel C confirming presence of epithelial glands (arrowhead); Bv
indicates background fluorescence from a blood vessel. (Panel E) CK8
staining in control ovary marks OSE cells (arrowheads) and oviductal
(Ovi) epithelial cells. (Panel F) CK8 expression in a typical small tumor in
Amhr2-Cre;Ctnnb1
D(ex3)/+ ovaries. (Panel G) Vimentin immunofluores-
cence in control ovaries was present in some stromal cells but not in
granulosa cells of follicles (outlined by dotted line, F). In Amhr2-
Cre;Ctnnb1
D(ex3)/+ ovaries (Panel H), vimentin expression was observed
throughout the tumors. (Panels I–L) Amh and inhibin-a expression in
control (I & K) and mutant (J & L) ovaries. Inhibin-a and Amh expression
was present in granulosa cells of the remnant follicles (arrow,
demarcated from the tumor by white dotted line) of mutant ovaries
but not in tumor areas (indicated with a T). Nuclei are stained with DAPI
in Panels D–L. Bars=50 um.
doi:10.1371/journal.pone.0020715.g002
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Cre;Ctnnb1
D(ex3)/+ ovaries. (Panel A–F) Colocalization of b-catenin and PTEN in serial sections of control (Ctnnb1
D(ex3)/+), Amhr2-Cre;Ctnnb1
D(ex3)/+ and
Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D ovaries. Insets in Panels B, E, & F are higher magnification images of areas marked by black rectangles. F: follicle, t: tumor.
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strong positive staining for vimentin in less differentiated areas of
pretumoral lesions and in fully-grown tumors, suggesting that
cancerous cells undergo epithelial mesenchymal transition (EMT)
in these tumors (Fig. 2H). Vimentin staining was observed in
stromal but not in granulosa cells of the control ovaries (Fig. 2G).
Since these tumors showed less differentiated morphology and
Amhr2-cre is also expressed in granulosa cells at later stages of
development [25], we examined expression of the ovarian
granulosa cell tumor markers to rule out the possibility that these
tumors might be derived from the granulosa cells. We analyzed the
expression of inhibin-a and anti-Mu ¨llerian hormone (AMH, also
known as Mu ¨llerian Inhibiting Substance [26]), which are the two
markers most often used to detect murine, human, and equine
granulosa cell tumors [27,28,29], in Amhr2-Cre;Ctnnb1
D(ex3)/+
tumors (Fig. 2I–L). Although expression of both was observed in
control follicles (Fig. 2I & K) and in the remaining follicles of early
tumors (Fig. 2J & L), expression of these two markers was not
observed in the tumorous areas.
PTEN deletion with constitutively activated (CA) b-
catenin leads to development of more aggressive tumors
Interactions between Wnt/b-catenin and Akt/PTEN signaling
pathways play animportant roleincarcinogenesis[6].Weexamined
the statusof PTENbyperforming immunohistochemical stainingfor
b-catenin and PTEN on serial sections of Amhr2-Cre;Ctnnb1
D(ex3)/+
ovaries and observed increased expression of PTEN in pretumoral
lesions with nuclear b-catenin (Fig. 3B & E). To examine whether
PTEN deletion could affect tumor progression in Amhr2-Cre;Ctnnb1-
D(ex3)/+ ovaries, we developed another mouse model by deleting exon
3o ft h eb-catenininPTENnegativecellsof themouse ovary(Amhr2-
Cre;Ctnnb1
D(ex3)/+;Pten
D/D) (Fig. 3C & F). These mice showed early
onset of tumor development and were euthanized because of tumor-
related morbidities (Fig. 3G & H). No evidence of ascites or
metastases was observed by gross examination of the peritoneal
cavity. The ovarian tumors in Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D
ovaries showed histopathological features similar to the tumors of
Amhr2-Cre;Ctnnb1
D(ex3)/+ mice (Fig. S2). Consistent with previous
observations [22,30], deletion of PTEN alone does not result in
ovarian tumor development (data not shown), suggesting that
activation of the phosphatidylinositol-39 kinase (PI3K) signaling
pathway with inactivating PTEN mutations alone may not be
sufficient for tumor initiation and needs to act in concert with other
oncogenes to cause cancer.
PTEN has been shown to regulate P53 protein levels and this
interaction plays a role in cellular senescence, growth inhibition, and
cellular transformation [31]. Additionally, dysregulated b-catenin
expression causes growth arrest and a senescent-like state in mouse
embryonicfibroblast cells (MEFs) and activation of b-catenin stimulates
proliferation of p53-deficient MEFs suggesting that the senescence
observed after activation of b-catenin is mediated by p53 [32]. In vivo,
p53 deficiency increases the tumorigenicity of intestinal tumors in
APC-deficient mice indicating that loss of p53 plays an important role
in the progression of these tumors [33]. We have observed early onset
of tumor development in Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/Dmice (Fig. 3G
& H). However, tumor progression has up to a year long latency period
in Amhr2-Cre;Ctnnb1
D(ex3)/+ mice (Fig. 3H) and no change was observed
in the mortality rate of these animals, even though the pretumoral
lesions were present in 4-week old ovaries (Fig. 1). We examined
whether the p53 senescence pathway might be involved in the
inhibition of tumor progression in the Amhr2-Cre;Ctnnb1
D(ex3)/+ ovaries,
which could account forthe discrepancyintimingof tumor progression
in these two genotypes. We found positive staining for SAb-gal, a
hallmark of senescent cells [34], in pretumoral lesions present in the
Amhr2-Cre;Ctnnb1
D(ex3)/+ ovaries (Fig. 3J). In contrast, SAb-gal staining
was absent in the Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D and control ovaries
(Fig. 3I & K). We then examined the proliferation index of these
tumors by phospho-histone H3 (pH3) immunofluorescence, a marker
for mitotic cells [35]. Very few pH3-positive cells were present in the
pretumoral lesions of Amhr2-Cre;Ctnnb1
D(ex3)/+ ovaries (Fig. 3M).
However, many more pH3-positive cells were present in the Amhr2-
Cre;Ctnnb1
D(ex3)/+;Pten
D/D tumors and control ovaries (Fig. 3L & N). To
ensure that these non-proliferating cells in the pretumoral ovaries are
not dead cells, we performed a TUNEL assay. The cells present in the
indolent pretumoral lesions of the Amhr2-Cre;Ctnnb1
D(ex3)/+ ovaries were
TUNEL-negative (Fig. 3P) and only a few TUNEL-positive cells were
present in Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D tumors (Fig. 3Q). As an
endogenous positive control for the assay, some TUNEL positive cells
were present in the atretic follicles of the control ovaries (Fig. 3O).
To examine the possible mechanisms involved in the induction of
senescence in the Amhr2-Cre;Ctnnb1
D(ex3)/+ ovaries, we performed
western blot and IHC analyses of various proteins involved in the
induction of senescence [36]. We found increased expression of p53
(Fig. 3S & X) and p21 (Fig. 3X) in the Amhr2-Cre;Ctnnb1
D(ex3)/+
ovaries. However, p53 and p21 expression were decreased in
ovaries also deleted for PTEN (Fig. 3T & X), suggesting that the
p53-p21 senescence pathway was functional and responsible for
tumor inhibition in Amhr2-Cre;Ctnnb1
D(ex3)/+ ovaries. We also
investigated whether the elevated levels of p53 and p21 might be
the related to increased DNA damage, an early event in
tumorigenesis and showed that c-H2AX, the phosphorylated form
of the core histone H2AX and a marker for double-stranded DNA
breakage, was highly expressed in both Amhr2-Cre;Ctnnb1
D(ex3)/+ and
Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D tumor cells compared to control
ovarian tissue (Fig. 3 U–W). Unlike most in vitro studies [32], we
observed no noticeable difference in p19
arf and p16
ink4a protein
levels suggesting limited involvement of these cell cycle regulators in
these in vivo model systems (Fig. 3X). The expression of another cell
cycle regulator, p27
kip1, was marginally reduced in both Amhr2-
Cre;Ctnnb1
D(ex3)/+ and Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D tumors com-
pared to control (Fig. 3X). Additionally, protein levels of phospho-
S6 kinase (pS6K) were increased in Amhr2-Cre;Ctnnb1
D(ex3)/+ and
Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D ovaries, suggesting that the mTOR
pathway is activated during development of these tumors (Fig. 3X).
(Panel G & H) Gross analyses of the reproductive tracts from the indicated mice show large tumors by 6 weeks in Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D ovaries
but relatively normal size ovaries in Amhr2-Cre;Ctnnb1
D(ex3)/+ mice . SAb-gal staining was observed in Amhr2-Cre;Ctnnb1
D(ex3)/+ ovaries but not in control or
Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D ovaries (I–K). Comparedtocontrolsand Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D ovaries, very fewpH3 positive cells werepresent
inprecancerouslesions (whitedottedlines)ofAmhr2-Cre;Ctnnb1
D(ex3)/+ovaries (L–N).AbsenceofTUNEL staininginpretumoral lesions (whitedottedlines)
showedthatnon-proliferatingcells in Amhr2-Cre;Ctnnb1
D(ex3)/+ovaries arenot apoptotic (O–Q).Immunohistochemicalanalysesshowedanincreaseinp53
accumulation in Amhr2-Cre;Ctnnb1
D(ex3)/+ tumors compared to controls and loss of p53 expression in Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D tumors (R–T).
Evidence of DNA damage determined by staining for c-H2AX and observed in the tumors of both mutants (V & W) but not in the control ovaries (U). The
differential expression of p53 was confirmed by Western blot analyses with pooled ovarian lysates (n=4) and repeated three times (Panel X), which also
confirmedthepresenceofexon3deletedb-catenin(arrowhead)inAmhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/Dovaries.Analysesalsoshowedincreasedexpressionof
pAKT and pS6K, and decreased expression of p21 and p27kip1 in Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D ovaries. b-actin was used as a loading control.
Bars=50 um.
doi:10.1371/journal.pone.0020715.g003
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treatment reduces tumor burden
Mammalian target of rapamycin (mTOR) signaling is a master
regulator of cellular proliferation and is an attractive therapeutic
target for a variety of cancers [37]. Dysregulated Wnt/b-catenin
signaling has been shown to induce mTOR expression and
signaling in intestinal polyps [38] of mutant APC mice, and we
have shown that mTOR expression is elevated in uteri of Amhr2-
Cre;Ctnnb1
D(ex3)/+ mice [19]. In Fig. 3X, we observed elevated
expression by western analysis of pS6K, a downstream target of
mTOR kinase activity, in the Amhr2-Cre;Ctnnb1
D(ex3)/+ and Amhr2-
Cre;Ctnnb1
D(ex3)/+;Pten
D/D tumors compared to control mice.
Immunohistochemistry of mTOR, p mTOR, and pS6K expres-
sion was performed to confirm that the increased expression was
isolated to the tumor cells in mutant ovaries (Fig. 4A–I). We also
observed strong expression for mTOR, p mTOR, and pS6K in
human OEAs (4/4) (Fig. 4J–Q), which in Fig. 1, we showed also
had induced levels of nuclear b-catenin.
The upregulation of mTOR activity is commonly observed in colon,
urinary bladder, and salivary gland cancers formed after dysregulated
Figure 4. Elevated levels of active mTOR in mouse ovarian tumors and in human OEAs. Sections from ovaries of control (A, D, & G) and
mutant mice (B, C, E, F, H, & I) were analyzed by IHC for mTOR, pmTOR, and pS6K, as indicated. IHC of mTOR (J & N) , pmTOR (K & O), S6K (L & P) and
pS6K (M & Q) in normal postmenopausal ovaries (n=3) and in human OEAs (n=4) as indicated. Bars=50 um.
doi:10.1371/journal.pone.0020715.g004
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pS6K protein levels in tumors formed in the mouse models (Amhr2-
Cre;Ctnnb1
D(ex3)/+ and Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D) and in human
OEAs, we speculated that the mTOR pathway might also be involved
in the growth of these tumors. Tumor cells were collected from Amhr2-
Cre;Ctnnb1
D(ex3)/+;Pten
D/D mutant ovaries and injected into the dorsal
flanks of 10 NOD/SCID mice in order control for uniformity at the
s t a r to ft h ee x p e r i m e n t .A f t e rt h ef i r s tw e e k ,f i v em i c ew e r er a n d o m l y
assigned to either a rapamycin-treated group or a vehicle-treated
group. Significantly reduced tumor growth was observed in mice
treated with rapamycin for 12 weeks by oral gavage, compared to the
vehicle-treated controls (Fig. 5A). The tumor volume and weight were
significantly lower in the rapamycin-treated group compared to the
control group (Table 2). Rapamycin treatment in cancer cell lines and
in vivo mouse models induces growth arrest and apoptosis [41]. We
investigated the inhibitory effect of rapamycin in these tumors by
analyzing the proliferation index and apoptotic rate compared to
control-treated tumors (Fig. S3). Rapamycin-treated tumors had 1/3
rd
the number of proliferating pH3-positive cells than the vehicle-treated
tumors (Table 2), suggesting that rapamycin treatment decreased the
proliferation rate of the tumor cells. TUNEL and activated Caspase 3
immunostaining showed that rapamycin treatment also resulted in a
significant increase in cell death compared to the vehicle-treated
tumors (Table 2 & Fig. S3). To confirm that rapamycin treatment
inhibited the activation of mTOR signaling in the treated tumors, we
performed immunohistochemical staining for pS6K. In Fig. 5B & C,
we show a representative example from one of the 5 vehicle-treated
tumors with strong pS6K immunostaining, whereas little pS6K
immunostaining was detected in 100% (5/5) of the rapamycin-treated
tumors examined. These findings indicate that rapamycin treatment
significantly decreased tumor burden by inhibiting mTOR activity,
mainly by reducing proliferation and increasing cell death. We also
performed histological examination of vehicle- and rapamycin-treated
tumors. Similar to primary tumors, grafted tumors showed epithelial
glands admixed with less differentiated tumor cells (Fig. 5D & E).
Colocalization of vimentin (a mesenchymal marker) and cytokeratin
(an epithelial marker) in the grafted tumors showed that tumors were
strongly positive for cytokeratin and some areas of tumors were positive
for both markers (Fig. 5F & G), suggesting that epithelial
to mesenchymal (EMT) transition might be occurring in the
allotransplants.
Discussion
Most ovarian carcinomas are thought to originate from the
mesothelial cells covering of the ovary known as the OSE [4].
However, the histology of the most common human epithelial
ovarian cancers is more similar to the fallopian tube (serous),
uterus (endometrioid) and cervix (mucinous) [4]. It is not known
how this simple monolayer of cells gives rise to such a complex
disease and why ovarian carcinomas are so similar to the
Mu ¨llerian duct-derived tissues. During development, Mu ¨llerian
duct epithelia commit to the specific lineages by acquiring a
fallopian, uterine, or cervical phenotypes due, in part, to the
segmental expression of Hoxa genes [42,43]. However, OSE cells
maintain a primitive multipotential phenotype [44]. It has been
suggested that over time these cells accumulate various genetic
Table 2. Morphometric Analyses of Tumor Grafts.
Rapamycin;
mean ± SEM
Vehicle;
mean ± SEM p value
Body weight (g) 22.260.3 22.560.7 0.97
Tumor volume (mm
3) 5.963.7 702.26256.9 0.02
Tumor weight (mg) 9.062.4 335.06135.6 0.03
TUNEL
a 62.0612.1 6.362.0 0.01
pH3
a 39.262.1 176.5645.9 0.04
Activated Caspase 3
a 10.261.8 1.460.1 0.01
aPositive cells/field.
doi:10.1371/journal.pone.0020715.t002
Figure 5. Rapamycin treatment reduced tumor burden by
inhibiting mTOR activity and controlling cell proliferation and
death. (Panel A) Tumor size was significantly decreased in rapamycin-
treated mice compared to vehicle-treated controls. *One of the vehicle-
treated mice was euthanized early because the tumor had grown too
large and was excluded from morphometric measurements. (Panel B &
C) pS6K immunostaining of tumors (n=5) showed that vehicle-treated
tumors were strongly positive; whereas rapamycin treated tumors
(n=5) were negative. (Panel D & E) H&E staining revealed distinct
epithelial glands similar to primary tumors. Panel E is the higher
magnification image of area marked by a rectangle in Panel D.
Colocalization of vimentin (red) and cytokeratin (green) revealed that
these tumors are strongly positive for cytokeratin (F). Occasional tumor
lesions expressing both markers (G), vimentin (red, asterisk) and
cytokeratin (green, arrowheads) were also observed. Bars=50 um.
doi:10.1371/journal.pone.0020715.g005
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ation to the various lineages of ovarian tumors [4,45]. Other
studies have suggested alternative sites, like the distal end of
fimbriae and secondary Mu ¨llerian duct system, as the points of
origin for ovarian carcinomas [3,45]. Additionally, endometriotic
lesions have been suggested as the precursor for OEAs,
particularly those with b-catenin and PTEN mutations [46].
Our results favor the OSE origin hypothesis, at least for OEA
development, since we observed tumors arising in the OSE that
can differentiate into the OEA histotype.
In human colorectal cancers, tumor cells with nuclear accumu-
lation of b-catenin undergo growth arrest and EMT [47,48]. These
cells progressively lose E-cadherin, an epithelial marker, and
acquire fibronectin expression, a mesenchymal marker [47,48].
Furthermore, Wnt signaling has been shown to promote EMT and
a tumorinvasion ofthebreast and cervicalcancercells byregulating
Snail activity [49]. The forced expression of Snail and Slug in
ovarian cancer cell lines suppresses E-cadherin levels, which
correlates with the induction of an EMT-like state and generation
of cancer cells with stem cell characteristics [50]. In a previous
report, it was observed that combined deletion of APC and PTEN
causes formation of ovarian epithelial tumors accompanied by loss
of E-cadherin expression and appearance of mesenchymal like-cells
suggesting EMT [6]. Our results showing expression of both
mesenchymal and epithelial markers in the tumors (Figs. 2 & 5) also
suggested that EMT occurs during the development of ovarian
carcinoma with dysregulated Wnt/b-catenin signaling. Preliminary
studies to investigate this possibility showed upregulated expression
of Snail and Slug in the tumors by immunofluorescence (data not
shown) but more detailed mechanistic studies are required to
determine whether dysregulated Wnt/b-catenin expression is
driving EMT, which then leads to tumor development, or whether
EMT is the result of tumor development.
In previous reports [51,52], appearance of these mesenchymal
cells was considered a malignant transformation of granulosa cells,
which led to their classification as granulosa cell tumors of the
ovary, even though the markers for granulosa cells were not
reported. However, we showed that these tumors failed to express
markers of granulosa cell tumors (AMH and inhibin-a), and
express epithelial markers suggesting an epithelial origin for these
tumors (Fig. 2). Consistent with our results, ovarian tumors formed
in APC-PTEN knockout model were also negative for inhibin-a
staining [6]. Recently, Fan et al. specifically activated b-catenin in
granulosa cells of the mouse ovary by conditional deleting exon3
(Ex3) of b-catenin using Cyp19-cre and observed no tumor
formation in these mutant mice (Cyp19-Cre;Ctnnb1
D(ex3)/+) [53].
Furthermore, only membranous but not nuclear b-catenin
expression is observed in human granulosa cell tumor patient
samples [28], suggesting Wnt/b-catenin signaling does not play a
role in either mouse or human granulosa cell tumor development.
Alternatively, granulosa cells are thought to originate from the
coelomic epithelium of the ovary during the perinatal period [54],
which could classify the cells in these reports as ‘‘pregranulosa’’
cells that can differentiate into either granulosa cell tumors or
ovarian mesenchymal tumors, depending on the context.
Lastly, our findings, along with those of others [55], provide an
exciting prospect for using mTOR inhibitors together with other
therapies in the treatment of ovarian carcinomas. mTOR is a
critical regulator of cell growth and proliferation, and activation of
this pathway occurs in many tumors including colon, ovarian, and
uterine [19,38,41,55]. Activation of Wnt/b-catenin has been
shown to upregulate mTOR activity in colon and uterine cancers
[19,38], and treatment with an mTOR-specific inhibitor sup-
presses polyp formation in a colon cancer mouse model [38]. In
this study, we have shown that activation of b-catenin and/or
AKT increases mTOR activity and that inhibition of that activity
with rapamycin suppresses the tumor burden by controlling cell
proliferation and death. Everolimus (a rapamycin derivative)
treatment has been shown to reduce tumor growth of cisplastin-
resistant clear cell ovarian carcinoma cells [56] and both the onset
and progression of ovarian cancer in a mouse model expressing
SV40 Large T antigen driven by the MIS type II receptor (Amhr2)
promoter [2,56]. Presently, mTOR inhibitors are in phase I–III
trials for other solid tumors [41]. In light of our studies, their use in
OEA-specific trials should also be considered.
Supporting Information
Figure S1 No abnormalities were present in the control
(Ctnnb1
D(ex3)/+) adult ovaries (A & B). In adult mutant (Amhr2-
Cre;Ctnnb1
D(ex3)/+) ovaries, cancerous lesions were present through-
out the ovary and in the intrabursal space (arrowheads) (C–E). b-
catenin staining in adult mutant ovaries (F). Bars represent 50 um.
(TIF)
Figure S2 H&E staining of 10-day old ovaries from control and
mutant (Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D)m i c e( P a n e lA – C ) .R e p r e s e n -
tative section oftumor from 8 week-old Amhr2-Cre;Ctnnb1
D(ex3)/+;Pten
D/D
mice (Panel D). Bars represent 50 um.
(TIF)
Figure S3 Rapamycin treatment of tumors decreased prolifer-
ation and increased cell death. Staining for pH3 (A–F, green),
TUNEL (G–L, green), and activated caspase 3 (M–R, red) was
performed on three different tumors derived from three different
animals. Nuclei were counterstained with DAPI. Bars represent
50 um.
(TIF)
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